RU2451029C2 - Производное инсулина - Google Patents

Производное инсулина Download PDF

Info

Publication number
RU2451029C2
RU2451029C2 RU2008143668/04A RU2008143668A RU2451029C2 RU 2451029 C2 RU2451029 C2 RU 2451029C2 RU 2008143668/04 A RU2008143668/04 A RU 2008143668/04A RU 2008143668 A RU2008143668 A RU 2008143668A RU 2451029 C2 RU2451029 C2 RU 2451029C2
Authority
RU
Russia
Prior art keywords
insulin
derivative
group
human insulin
amino acid
Prior art date
Application number
RU2008143668/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2008143668A (ru
Inventor
Франтишек ХУБАЛЕК (DK)
Франтишек ХУБАЛЕК
Томас ХОЕГ-ЙЕНСЕН (DK)
Томас ХОЕГ-ЙЕНСЕН
Иб ЙОНАССЕН (DK)
Иб ЙОНАССЕН
Патрик Уилльям ГЭРИБЭЙ (DK)
Патрик Уилльям ГЭРИБЭЙ
Палле ЯКОБСЕН (DK)
Палле ЯКОБСЕН
Свенд ХАВЕЛУНД (DK)
Свенд ХАВЕЛУНД
Янош Тибор КОДРА (DK)
Янош Тибор КОДРА
Original Assignee
Ново Нордиск А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ново Нордиск А/С filed Critical Ново Нордиск А/С
Publication of RU2008143668A publication Critical patent/RU2008143668A/ru
Application granted granted Critical
Publication of RU2451029C2 publication Critical patent/RU2451029C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RU2008143668/04A 2006-05-09 2007-05-08 Производное инсулина RU2451029C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP06113709.7 2006-05-09
EP06113709 2006-05-09
EP06118260 2006-08-01
EP06118260.6 2006-08-01

Publications (2)

Publication Number Publication Date
RU2008143668A RU2008143668A (ru) 2010-06-20
RU2451029C2 true RU2451029C2 (ru) 2012-05-20

Family

ID=38668119

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008143668/04A RU2451029C2 (ru) 2006-05-09 2007-05-08 Производное инсулина

Country Status (13)

Country Link
US (1) US8933021B2 (https=)
EP (2) EP2015770B1 (https=)
JP (1) JP5269767B2 (https=)
KR (1) KR101441444B1 (https=)
AU (1) AU2007247109B2 (https=)
BR (1) BRPI0712041A2 (https=)
CA (1) CA2649235A1 (https=)
ES (2) ES2395738T3 (https=)
IL (1) IL194312A0 (https=)
MX (1) MX2008014061A (https=)
NO (1) NO20085056L (https=)
RU (1) RU2451029C2 (https=)
WO (1) WO2007128817A2 (https=)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2531988C (en) * 2003-08-05 2016-06-28 Novo Nordisk A/S Novel insulin derivatives
EP2256130B1 (en) 2005-02-02 2013-09-25 Novo Nordisk A/S Novel insulin derivatives
US20080171695A1 (en) 2005-02-02 2008-07-17 Novo Nordisk A/S Insulin Derivatives
ES2371361T3 (es) * 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
DE602007009496D1 (de) * 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
WO2007128815A1 (en) 2006-05-09 2007-11-15 Novo Nordisk A/S Insulin derivative
RU2524150C2 (ru) 2006-09-22 2014-07-27 Ново Нордиск А/С Аналоги инсулина, устойчивые к протеазам
US10100098B2 (en) 2006-12-13 2018-10-16 Stelis Biopharma Private Limited Insulin production methods and proinsulin constructs
US20120214963A1 (en) * 2011-02-23 2012-08-23 Elona Biotechnologies Aspart proinsulin compositions and methods of producing aspart insulin analogs therefrom
JP5496082B2 (ja) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
JP5552046B2 (ja) 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2217621B1 (en) 2007-11-08 2015-04-22 Novo Nordisk A/S Insulin derivative
BRPI0820535B8 (pt) * 2007-11-16 2021-05-25 Novo Nordisk As composições farmacêuticas contendo insulina e um peptídeo insulinotrópico
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
JP4959005B2 (ja) * 2008-10-30 2012-06-20 ノボ・ノルデイスク・エー／エス 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
PL2632478T3 (pl) * 2010-10-27 2020-03-31 Novo Nordisk A/S Leczenie cukrzycy z zastosowaniem zastrzyków insuliny podawanych w różnych odstępach czasu
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
SI2651398T1 (en) 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
WO2012104339A1 (en) * 2011-02-01 2012-08-09 Novo Nordisk A/S Purification of insulin
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
KR102093463B1 (ko) * 2011-04-12 2020-03-26 노보 노르디스크 에이/에스 이중 아실화된 ｇｌｐ-1 유도체
PL2696687T3 (pl) 2011-04-12 2017-06-30 Novo Nordisk A/S Pochodne podwójnie acylowanej GLP-1
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
HRP20181447T1 (hr) 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
PT2827845T (pt) 2012-03-22 2019-03-29 Novo Nordisk As Composições compreendendo um agente de entrega e sua preparação
CN104364260B (zh) 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
EP2844274B1 (en) 2012-05-01 2019-03-20 Novo Nordisk A/S Pharmaceutical composition
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
US9457096B2 (en) 2012-07-06 2016-10-04 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
TWI780236B (zh) * 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
KR102272671B1 (ko) 2013-05-02 2021-07-06 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
JP6499184B2 (ja) 2013-10-07 2019-04-10 ノヴォ ノルディスク アー／エス インスリン類似体の新規な誘導体
MX2016008979A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
PE20210857A1 (es) 2016-12-16 2021-05-18 Novo Nordisk As Composiciones farmaceuticas que contienen insulina
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
KR20210102347A (ko) 2018-12-11 2021-08-19 사노피 인슐린 수용체 결합 친화성이 감소된 인슐린 유사체
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
CN118754967A (zh) * 2019-12-30 2024-10-11 甘李药业股份有限公司 胰岛素衍生物

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
WO1995007931A1 (en) * 1993-09-17 1995-03-23 Novo Nordisk A/S Acylated insulin
WO1996029344A1 (en) * 1995-03-17 1996-09-26 Novo Nordisk A/S Insulin derivatives
WO1997031022A1 (en) * 1996-02-21 1997-08-28 Novo Nordisk A/S Insulin derivatives and their use
WO1998002460A1 (en) * 1996-07-11 1998-01-22 Novo Nordisk A/S Selective acylation method
RU2160118C2 (ru) * 1994-11-17 2000-12-10 Эли Лилли Энд Компани Ацилированные аналоги инсулина
WO2003013573A1 (en) * 2001-08-10 2003-02-20 Epix Medical, Inc. Polypeptide conjugates with extended circulating half-lives
WO2005005477A2 (en) * 2003-07-11 2005-01-20 Novo Nordisk A/S Stabilised insulin compositions
WO2005012347A2 (en) * 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives
WO2005012346A1 (en) * 2003-07-25 2005-02-10 Conjuchem, Inc. Long lasting insulin derivatives and methods thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3528960A (en) * 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
JP3018463B2 (ja) 1989-10-19 2000-03-13 日本油脂株式会社 グルコース応答性薬物放出複合体
DK10191D0 (da) * 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
US6011007A (en) * 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US6869930B1 (en) * 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US5905140A (en) * 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
WO1999034821A1 (en) * 1998-01-09 1999-07-15 Novo Nordisk A/S Stabilised insulin compositions
AU2003208316A1 (en) * 2002-03-13 2003-09-22 Novo Nordisk A/S Minimising body weight gain in insulin treatment
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
EP1687428A1 (en) 2003-11-14 2006-08-09 Novo Nordisk A/S Processes for making acylated insulin
BRPI0416041A (pt) 2003-11-14 2007-01-02 Univ Tennessee locus da micolactona: uma linha de montagem para produção de novos policetìdeos com usos terapêutico e profilático
WO2006008238A1 (en) 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
EP1769049A2 (en) 2004-07-16 2007-04-04 Ciba Specialty Chemicals Holding Inc. Luminescent silicon oxide flakes
EP2256130B1 (en) * 2005-02-02 2013-09-25 Novo Nordisk A/S Novel insulin derivatives
US20080171695A1 (en) * 2005-02-02 2008-07-17 Novo Nordisk A/S Insulin Derivatives
DE102005062618B4 (de) 2005-12-23 2008-05-08 Carl Zeiss Smt Ag Optische Abbildungseinrichtung und Abbildungsverfahren mit Bestimmung von Abbildungsfehlern
ES2371361T3 (es) * 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
DE602007009496D1 (de) 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
WO2007104737A1 (en) * 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
WO2007128815A1 (en) * 2006-05-09 2007-11-15 Novo Nordisk A/S Insulin derivative
JP5552046B2 (ja) * 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
EP2217621B1 (en) * 2007-11-08 2015-04-22 Novo Nordisk A/S Insulin derivative
WO2009060072A1 (de) 2007-11-09 2009-05-14 Mann+Hummel Gmbh Filterelement für flüssigkeitsfilter und flüssigkeitsfilter
JP4959005B2 (ja) 2008-10-30 2012-06-20 ノボ・ノルデイスク・エー／エス 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
JP5823504B2 (ja) 2010-05-10 2015-11-25 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 少なくとも１種の脂肪族カルボン酸でエステル化されたグリセロールを可塑剤として含む、熱可塑性のポリウレタン
MX2012012943A (es) * 2010-05-10 2012-11-29 Novo Nordisk As Proceso para preparacion de complejos de insulina-cinc.

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
WO1995007931A1 (en) * 1993-09-17 1995-03-23 Novo Nordisk A/S Acylated insulin
RU2160118C2 (ru) * 1994-11-17 2000-12-10 Эли Лилли Энд Компани Ацилированные аналоги инсулина
WO1996029344A1 (en) * 1995-03-17 1996-09-26 Novo Nordisk A/S Insulin derivatives
WO1997031022A1 (en) * 1996-02-21 1997-08-28 Novo Nordisk A/S Insulin derivatives and their use
WO1998002460A1 (en) * 1996-07-11 1998-01-22 Novo Nordisk A/S Selective acylation method
WO2003013573A1 (en) * 2001-08-10 2003-02-20 Epix Medical, Inc. Polypeptide conjugates with extended circulating half-lives
WO2005005477A2 (en) * 2003-07-11 2005-01-20 Novo Nordisk A/S Stabilised insulin compositions
WO2005012346A1 (en) * 2003-07-25 2005-02-10 Conjuchem, Inc. Long lasting insulin derivatives and methods thereof
WO2005012347A2 (en) * 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives

Also Published As

Publication number Publication date
EP2015770A2 (en) 2009-01-21
RU2008143668A (ru) 2010-06-20
NO20085056L (no) 2008-12-03
WO2007128817A2 (en) 2007-11-15
US8933021B2 (en) 2015-01-13
BRPI0712041A2 (pt) 2011-12-27
WO2007128817A3 (en) 2008-03-06
US20090239785A1 (en) 2009-09-24
ES2548393T3 (es) 2015-10-16
EP2015770B1 (en) 2012-09-26
IL194312A0 (en) 2011-08-01
KR101441444B1 (ko) 2014-09-18
JP5269767B2 (ja) 2013-08-21
ES2395738T3 (es) 2013-02-14
EP2386572A1 (en) 2011-11-16
MX2008014061A (es) 2008-11-14
EP2386572B1 (en) 2015-07-08
AU2007247109A1 (en) 2007-11-15
AU2007247109B2 (en) 2012-03-15
KR20090018906A (ko) 2009-02-24
CA2649235A1 (en) 2007-11-15
JP2009536179A (ja) 2009-10-08

Similar Documents

Publication Publication Date Title
RU2451029C2 (ru) Производное инсулина
RU2470016C2 (ru) Производное бипиразола
AR071990A1 (es) Compuesto de insulina lispro pegilada, su uso para la manufactura de un medicamento util para el tratamiento de hipoglicemia o diabetes , composicion farmaceutica que lo comprende y proceso para elaborar dicho compuesto
EA200970287A1 (ru) Способы, соединения, композиции и носители, подходящие для доставки 3-амино-1-пропансульфоновой кислоты
JP2017512752A5 (https=)
WO2007016496A3 (en) Dipiperazinyl ketones and related analogues
EP2481402A3 (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
WO2005079391A3 (en) Contrast agents for myocardial perfusion imaging
JP2013526501A5 (https=)
JP2008528658A5 (https=)
EP1862458A3 (en) Therapeutic agents useful for treating pain
CA2452923A1 (en) Peptide-based compounds for targeting integrin receptors
WO2008000070B1 (en) Glycyrrhetinic acid derivatives
ATE486872T1 (de) Maleimid-derivate, pharmazeutische zusammensetzungen und verfahren zur behandlung von krebs
TR200401029T4 (tr) Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
EP2301531A3 (en) Combinations and modes of administration of therapeutic agents and combination therapy
EP1626055A3 (en) Non-mammalian GnRH analogs and uses thereof in the regulation of the immune system
CY1115719T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
RU2010136914A (ru) Средство и продукт питания для профилактики/уменьшения проявлений функционального расстройства пищеварения
ATE384526T1 (de) N-(((((1,3-thiazol-2- yl)amino)carbonyl)phenyl)sulphonyl)phenylalanin derivate und verwandte verbindungen zur behandlung von diabetes
EP3000481A3 (en) Peptide-mediated non-covalent delivery of active agent agents across the blood brain barrier
JP2023512501A5 (https=)
ATE496048T1 (de) Phenylcarboxamidverbindungen zur schmerzbehandlung
RU2013120135A (ru) Глюкозозависимые инсулинотропные пептидные аналоги
WO2005105159A3 (en) Contrast agents for myocardial perfusion imaging

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20150509